Smart Eye
GÖTEBORG, SE / ACCESSWIRE / November 12, 2021 / Smart Eye (STO:SEYE) (OTC PINK:SMTEF) (FRA:SE9)
At the extraordinary general meeting in Smart Eye Aktiebolag (publ), Reg. No. 556575-8371 (the "Company") held on 12 November 2021, the following resolutions were passed.
- The extraordinary general meeting resolved to approve the board of directors' resolution on a directed share issue of not more than 329,534 shares, entailing an increase of the share capital by not more than SEK 32,953.40. The shares have, with deviation from the shareholders' pre-emption rights, been allotted to Carnegie Investment Bank AB (publ) on behalf of a number of institutional investors. The subscription price at the time of the board of directors' resolution amounted to SEK 183 per share and was established through negotiations with certain institutional investors and is considered to constitute a fair market price. The reason for the deviation from the shareholders' pre-emption rights is to enable a raise of capital in order to ensure to in a flexible and cost-efficient manner raise capital to use as means of payment for the acquisition of iMotions A/S.
Following registration with the Swedish Companies Registration Office, the total number of share and votes in the Company will amount to 21,129,157. The share issue entails a dilution of approximately 1.56 per cent of the number of shares and votes in the Company. The share capital will increase from SEK 2,079,962.30 to SEK 2,112,915.70.
- The extraordinary general meeting resolved to authorise the board of directors to, on one or more occasions and with or without deviation from the shareholders' pre-emption rights, resolve on new share issues corresponding to the number of shares to be paid as consideration of the purchase price for the shares in iMotions A/S. Issues shall be carried out as in-kind issues. Issues may only be made on the terms agreed between the parties to the agreement to acquire the shares in iMotions A/S and the issue price shall be determined on market terms.
At the extraordinary general meeting, approximately 41 per cent of the votes were represented.
For further information, please contact
Martin Krantz, CEO Smart Eye AB
Phone: +46 70-329 26 98
Email: martin.krantz@smarteye.se
Anders Lyrheden, CFO Smart Eye AB
Phone: +46 70-320 96 95
Email: anders.lyrheden@smarteye.se
The information above was submitted for publication through the agency of the contact persons set out above, at 1.00 p.m. CET on 12 November 2021.
About Smart Eye
Smart Eye is the global leader in Human Insight AI, technology that understands, supports and predicts human behavior in complex environments. We bridge the gap between humans and machines for a safe and sustainable future.
Today, our technology is embedded in next-generation vehicles, leading the way towards human-centric mobility through Driver Monitoring Systems and Interior Sensing solutions. Our Research Instruments offer unparalleled insights into Automotive, Aviation & Aerospace, Assistive Technology, Media & Marketing, Psychology and many more fields. Our subsidiary Affectiva is pioneering Emotion AI, connecting machine logic with human empathy to gain a deeper understanding of how consumers engage with content and products.
Smart Eye was founded in 1999 and is headquartered in Sweden with offices in the US, UK, Germany, Egypt, Japan and China. A publicly traded company since 2016, our customers include NASA, Nissan, Boeing, Honeywell, Volvo, GM, BMW, Geely, Harvard University, 70% of the world's largest advertisers and 28% of the Fortune Global 500 companies.
SOURCE: Smart Eye
View source version on accesswire.com:
https://www.accesswire.com/672545/Bulletin-from-Extraordinary-General-Meeting-in-Smart-Eye-Aktiebolag-publ
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
GA-ASI and Saab Will Demonstrate AEW&C on MQ-9B in 202617.11.2025 03:05:00 CET | Press release
Two Aerospace Leaders Are Bringing Airborne Early Warning and Control to UAS DUBAI, UAE / ACCESS Newswire / November 16, 2025 / Following their announcement to bring Airborne Early Warning and Control (AEW&C) capability to the world's leading Remotely Piloted Aircraft (RPA) platform, General Atomics Aeronautical Systems, Inc. (GA-ASI) and Saab will now team up to demonstrate the capability in the summer of 2026. The demo will be conducted at GA-ASI's Desert Horizon flight operations facility in Southern California using a GA-ASI MQ-9B equipped with AEW&C supplied by Saab. In partnership with Saab, a leading company in AEW&C systems, GA-ASI is pairing Saab's AEW sensors with the world's longest-range, highest-endurance RPA, the MQ-9B. At sea or over land, adding AEW capabilities on MQ-9B enables persistent air surveillance and enables AEW in areas of the world where it doesn't currently exist or is unaffordable, such as for navy aircraft carriers at sea. "Adding AEW&C to the MQ-9B bring
Doha Tattoo Festival Announced as Ticket Sales Officially Open16.11.2025 12:45:00 CET | Press release
DOHA, QA / ACCESS Newswire / November 16, 2025 / Under the patronage of His Excellency Sheikh Khalifa bin Hamad bin Khalifa Al Thani, Minister of Interior and Commander of the Internal Security Force (Lekhwiya), the first edition of the Doha International Music and Marching Festival (Doha Tattoo) will be held from 16 to 20 December 2025 at Katara Cultural Village. A press conference held at Katara Cultural Village unveiled the line-up of participating bands and ticket details, attended by members of the Doha Tattoo organising committee and partner representatives. The Doha Tattoo will combine precision with musical artistry, showcasing performances by distinguished musical bands from seven countries: the United Kingdom, the United States of America, Turkia, Hashemite Kingdom of Jordan , the Sultanate of Oman, Kazakhstan, and the State of Qatar. The participating line-up includes the Irish Guards and the Royal Air Force Music Services from the United Kingdom, the United States Air Force
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
